SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Trial shows that risk of a major adverse cardiovascular event is eight per cent lower in people on new therapy ...

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

Eli Lilly (LLY) stock in focus as its diabetes drug Mounjaro causes heart benefits suceeding in a late-stage trial versus its ...

根据公司新闻稿，礼来心血管代谢健康部执行副总裁兼总裁Kenneth Custer表示："SURPASS-CVOT结果显示，Mounjaro保持了GLP-1受体激动剂Trulicity的心脏保护作用，同时提供了额外的益处。" ...

The limits on sales of Type 2 diabetes drugs tirzepatide and dulaglutide come after a 2023 regulation limited sales of semaglutide, which is sold under the band name Ozempic.

实验证实dulaglutide和romiplostim在皮下组织及淋巴液中发生蛋白区域降解，而abatacept和etanercept保持稳定，为临床给药方案优化提供新依据。 在生物制药领域，Fc融合蛋白因其通过IgG的Fc结构域延长半衰期的特性，已成为治疗多种疾病的重要武器。

New weight management drugs could be used to create a global metabolic health revolution and improve longevity, if investment ...

British Columbia's Health Ministry is limiting the sales of two more diabetes drugs to curb their off-label use for weight loss and preserve suppl.

British Columbia's Health Ministry is limiting the sales of two more diabetes drugs to curb their off-label use for weight loss and preserve supply for people who are diabetic. The limits on sales of ...